Template:Drug Development and Design

Thursday, June 3, 1:00 PM - 5:40 PM

Drug Development and Design

Kellas 104

Organizer/Presider: Jason Herr

1:00 Introductory Remarks

1:05 193 Discovering Drugs, Tools and Interesting Chemical Properties. Steven R. LaPlante, Boehringer Ingelheim (Canada) Ltd.

1:45 194 Novel 5-HT3 Receptor Modulators for the Potential Treatment of Irritable Bowel Syndrome. David D. Manning1, Christopher L. Cioffi1, Kristen N. Ryan1, Alexander Usyatinsky1, Kevin Fitzpatrick1, Carla Hassler1, Svetlana Dobritsa1, Cheng Guo1, Liaqat Masih1, Zhenjun Zhang1, Sok Hui Choo1, Jonathan D. Wierschke1, William G. Earley1, Peter R. Guzzo1, Marlene L. Cohen2, Amy S. Butler3, Catherine A. Brady3 and Nicholas M. Barnes3, (1)AMRI, (2)Creative Pharmacology Solutions LLC, (3)Celentyx Ltd.

2:25 195 Rethinking Natural Products in the Light of New Synthetic Methodologies. Mark Behnke, MLBehnke Consulting

3:05 Intermission

3:10 196 Drug Development and Design: Fundamental Concepts in Scaling from Milligrams to Kilograms. Robert Norrie, AMRI

3:50 197 Recent Development in Catalysis at BI. Wenjun Tang, Boehringer Ingelheim Pharmaceuticals Inc

4:30 Intermission